Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$162.14M$162.14M+38.3% vs Q1 2022 Net Income$39.62M$39.62M−34.1% vs Q1 2022 EPS Diluted$0.29$0.29−32.6% vs Q1 2022 Operating Income$53,802,000−28.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Free Cash Flowderived$75,587,000+59.8% Margins · derivedOperating margin33.2%−31.3 pt vs Q1 2022
Net margin24.4%−26.8 pt vs Q1 2022
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end